Suppr超能文献

用于与中枢神经系统受体结合的烷基化四氢异喹啉结构元件的合成与评估。

Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.

作者信息

Ofori Edward, Zhu Xue Y, Etukala Jagan R, Bricker Barbara A, Ablordeppey Seth Y

机构信息

Division of Basic Pharmaceutical Sciences, Florida A&M University, College of Pharmacy and Pharmaceutical Sciences, Tallahassee, FL 32307, USA.

出版信息

Bioorg Med Chem. 2016 Nov 15;24(22):5730-5740. doi: 10.1016/j.bmc.2016.09.019. Epub 2016 Sep 10.

Abstract

Diseases of the CNS are often complex and involve multiple receptor systems and thus, the treatment options for these diseases must focus on targeting the multiple receptors implicated in the various disorders. Schizophrenia and depression are examples of such diseases and their pharmacotherapy thus depends on agents which target multiple receptors including the dopamine, serotonin and even cholinergic receptors at the same time. In our previous campaign to find multi-receptor ligands, we have identified the benzothiazole 1a as an initial lead molecule. In the current work, we have expanded the structure affinity relationship (SAFIR) of 1a resulting in the identification of a partially restrained butyrophenone 3j as a potent and selective dual 5-HT and 5-HT receptor ligand. It is expected that compound 3j may serve as a new lead for further development in our search for newer and novel ligands with the potential to treat diseases of CNS origin.

摘要

中枢神经系统疾病通常很复杂,涉及多个受体系统,因此,这些疾病的治疗方案必须专注于针对各种疾病中涉及的多个受体。精神分裂症和抑郁症就是这类疾病的例子,它们的药物治疗因此依赖于同时作用于包括多巴胺、5-羟色胺甚至胆碱能受体在内的多个受体的药物。在我们之前寻找多受体配体的研究中,我们已确定苯并噻唑1a为初始先导分子。在当前的工作中,我们扩展了1a的结构亲和力关系(SAFIR),从而确定了一种部分受限的丁酰苯3j,它是一种有效且选择性的5-羟色胺和5-羟色胺受体双重配体。预计化合物3j可能作为新的先导物,用于我们进一步寻找有潜力治疗中枢神经系统源性疾病的更新颖配体的研究中。

相似文献

2
Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.5-羟色胺1A和5-羟色胺7受体双重配体的设计与合成。
Bioorg Med Chem. 2016 Aug 15;24(16):3464-71. doi: 10.1016/j.bmc.2016.05.053. Epub 2016 May 27.
3
New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263.新型双重 5-HT1A 和 5-HT7 受体配体源自 SYA16263。
Eur J Med Chem. 2021 Mar 15;214:113243. doi: 10.1016/j.ejmech.2021.113243. Epub 2021 Feb 3.

引用本文的文献

2
New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263.新型双重 5-HT1A 和 5-HT7 受体配体源自 SYA16263。
Eur J Med Chem. 2021 Mar 15;214:113243. doi: 10.1016/j.ejmech.2021.113243. Epub 2021 Feb 3.
5
New analogs of SYA013 as sigma-2 ligands with anticancer activity.新型 SYA013 类似物作为具有抗癌活性的 sigma-2 配体。
Bioorg Med Chem. 2019 Jun 15;27(12):2629-2636. doi: 10.1016/j.bmc.2019.04.012. Epub 2019 Apr 8.

本文引用的文献

1
Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.5-羟色胺1A和5-羟色胺7受体双重配体的设计与合成。
Bioorg Med Chem. 2016 Aug 15;24(16):3464-71. doi: 10.1016/j.bmc.2016.05.053. Epub 2016 May 27.
3
Identification of a new selective dopamine D4 receptor ligand.一种新型选择性多巴胺D4受体配体的鉴定。
Bioorg Med Chem. 2014 Jun 15;22(12):3105-14. doi: 10.1016/j.bmc.2014.04.026. Epub 2014 Apr 20.
7
Serotonergic drugs for depression and beyond.用于治疗抑郁症及其他疾病的血清素能药物。
Curr Drug Targets. 2013 May 1;14(5):578-85. doi: 10.2174/1389450111314050007.
8
Serotonin receptors involved in antidepressant effects.涉及抗抑郁作用的血清素受体。
Pharmacol Ther. 2013 Jan;137(1):119-31. doi: 10.1016/j.pharmthera.2012.09.006. Epub 2012 Sep 26.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验